What is Mega Lifesciences PCL Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Mega Lifesciences PCL's annualized net income for the quarter that ended in Mar. 2025 was ฿1,799 Mil. Mega Lifesciences PCL's average shareholder tangible equity for the quarter that ended in Mar. 2025 was ฿8,782 Mil. Therefore, Mega Lifesciences PCL's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was 20.49%.
The historical rank and industry rank for Mega Lifesciences PCL's Return-on-Tangible-Equity or its related term are showing as below:
BKK:MEGA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 17.73 Med: 25.91 Max: 31.8
Current: 24.25
During the past 13 years, Mega Lifesciences PCL's highest Return-on-Tangible-Equity was 31.80%. The lowest was 17.73%. And the median was 25.91%.
BKK:MEGA's Return-on-Tangible-Equity is ranked better than 84.42% of 905
companies
in the Drug Manufacturers industry
Industry Median: 6.46
vs BKK:MEGA: 24.25
Mega Lifesciences PCL Return-on-Tangible-Equity Historical Data
The historical data trend for Mega Lifesciences PCL's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Mega Lifesciences PCL Return-on-Tangible-Equity Chart
Competitive Comparison of Mega Lifesciences PCL's Return-on-Tangible-Equity
For the Drug Manufacturers - Specialty & Generic subindustry, Mega Lifesciences PCL's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mega Lifesciences PCL's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mega Lifesciences PCL's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Mega Lifesciences PCL's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Mega Lifesciences PCL (BKK:MEGA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Mega Lifesciences PCL Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Mega Lifesciences PCL's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BKK:MEGA has been successfully added to your 